Moneycontrol
Get App
Last Updated : Apr 08, 2011 12:22 PM IST | Source: CNBC-TV18

Indoco Remedies can test Rs 600: SP Tulsian

Indoco Remedies can test Rs 600, says SP Tulsian, sptulsian.com.


Indoco Remedies can test Rs 600, says SP Tulsian, sptulsian.com.


Tulsian told CNBC-TV18, "Indoco Remedies is into the Active Pharmaceutical Ingredient (API) and formulations. They have six manufacturing plants. They have brand product portfolio of 135 products, of which 14 products are in top three brands category. They have presence in 35 countries, of which many regulated markets are also included."


He further added, "If you go by the financial performance for the first nine months, the company has posted earnings per share (EPS) of Rs 33 on a top-line of about close Rs 370 crore. And this performance was achieved by the company in whole of FY10. So, already the company is on a path of showing a growth of about 35-40% in FY11. They should be able to post an EPS of close to about Rs 45 per share for FY11, which could rise to about Rs 52-54 for FY12."


"The company has a very small debt of about Rs 40-45 crore which is largely used by the company for working capital. So, if I take an analysis, it can be called as a debt free company. It is available at a PE multiple of close to about 10 or 11 on the historic earning. So, amongst the midcap pharma, this looks quite an interesting stock. I am expecting a price of may be about Rs 600 in next eight-ten months time."



Exclusive offer: Use code "BUDGET2020" and get Moneycontrol Pro's Subscription for as little as Rs 333/- for the first year.

First Published on Apr 8, 2011 11:31 am
Sections
Follow us on